New vaccine combo aims to boost cervical cancer treatment
NCT ID NCT04580771
First seen Nov 01, 2025 · Last updated May 06, 2026 · Updated 23 times
Summary
This study tests whether adding an experimental vaccine (PDS0101) to standard chemotherapy and radiation is safe and effective for people with locally advanced cervical cancer. The vaccine helps the immune system recognize and attack HPV-related tumor cells. About 22 adults with stage IB3 to IVA cervical cancer will receive the combination treatment. The main goal is to check for serious side effects, and researchers will also measure how well the tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IB3 CERVICAL CANCER FIGO 2018 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.